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Genome-wide expression analysis reveals diverse effects of 
acute nicotine exposure on neuronal function-related genes 
and pathways
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Previous human and animal studies demonstrate that acute nicotine exposure has complicated 
influences on the function of the nervous system, which may lead to long-lasting effects on 
the behavior and physiology of the subject. To determine the genes and pathways that might 
account for long-term changes after acute nicotine exposure, a pathway-focused oligoarray 
specifically designed for drug addiction research was used to assess acute nicotine effect on 
gene expression in the neuron-like SH-SY5Y cells. Our results showed that 295 genes involved 
in various biological functions were differentially regulated by 1 h of nicotine treatment. Among 
these genes, the expression changes of 221 were blocked by mecamylamine, indicating that the 
majority of nicotine-modulated genes were altered through the nicotinic acetylcholine receptors 
(nAChRs)-mediated signaling process. We further identified 14 biochemical pathways enriched 
among the nicotine-modulated genes, among which were those involved in neural development/
synaptic plasticity, neuronal survival/death, immune response, or cellular metabolism. In the genes 
significantly regulated by nicotine but blocked by mecamylamine, 13 enriched pathways were 
detected. Nine of these pathways were shared with those enriched in the genes regulated by 
nicotine, including neuronal function-related pathways such as glucocorticoid receptor signaling, 
p38 MAPK signaling, PI3K/AKT signaling, and PTEN signaling, implying that nAChRs play important 
roles in the regulation of these biological processes.  Together, our results not only provide insights 
into the mechanism underlying the acute response of neuronal cells to nicotine but also provide 
clues to how acute nicotine exposure exerts long-term effects on the nervous system.
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Although nicotine dependence is attributed mainly to repeated 
and chronic nicotine exposure, acute administration also can evoke 
noticeable physiological effects. For example, in humans, acute nic-
otine exposure, while significantly increasing the plasma nicotine 
concentration (Argacha et al., 2008), modulates a series of physi-
ological processes such as aortic wave reflection, arterial stiffness, 
and plasma asymmetrical dimethylarginine (ADMA) concentra-
tion (Adamopoulos et al., 2009). Experimentally, acute nicotine 
administration can significantly increase activation in multiple 
regions of mouse brain (Suarez et al., 2009) and induce spinal 
motor circuit output in embryonic zebrafish (Thomas et al., 2008). 
Previous studies have demonstrated the beneficial effect of acute 
nicotine exposure on cognitive performance (Foulds et al., 1996; 
Phillips and Fox, 1998; Ernst et al., 2001; Kumari et al., 2003), as 
well as its antidepressant effect (Tizabi et al., 2009).
Various genes and biochemical processes are involved in the 
biological  response  to  acute  nicotine  exposure.  These  include 
immediate-early  genes  such  as  c-FOS,  c-JUN,  NURR77,  and 
EGR1 (Ichino et al., 1999, 2002; Salminen et al., 1999) and the 
dendritically  targeted  early  response  genes  activity-regulated 
IntroductIon
Nicotine  is  the  dependence-inducing  constituent  underlying 
tobacco smoking. Through interactions with nicotinic acetylcho-
line receptors (nAChRs) in the central nervous system (CNS), nico-
tine exposure not only stimulates the mesocorticolimbic dopamine 
system in the outer shell of the nucleus accumbens (NAc) and other 
brain regions (Benwell and Balfour, 1992, 1997; Gaddnas et al., 
2001; Tammimaki et al., 2006) but also modulates the release of 
other neurotransmitters such as norepinephrine, serotonin, and 
GABA (Kenny et al., 2001; Barik and Wonnacott, 2006, 2009). 
Prolonged nicotine treatment can regulate the expression of genes/
proteins involved in various functions such as ERK1/2 and CREB 
(Brunzell et al., 2003), as well as their downstream targets such as 
c-FOS and FOSB (Pagliusi et al., 1996; Nisell et al., 1997; Soderstrom 
et al., 2007). Further, biochemical pathways underlying various 
physiological processes; e.g., MAPK signaling, phosphatidylinosi-
tol phosphatase signaling, growth factor signaling, and ubiquitin– 
proteasome pathways, are modulated by nicotine (Tang et al., 1998; 
Konu et al., 2001; Li et al., 2004). Through its direct or indirect 
interaction with these genes and biological pathways, nicotine is 
involved in the regulation of various physiological processes, such 
as learning and memory, angiogenesis, energy metabolism,   synaptic 
function, response to oxidative stress, and addiction (Harkness and 
Edited by:
Edythe D. London, University of 
California Los Angeles, USA
Reviewed by:
Herb Lachman, Albert Einstein College 
of Medicine of Yeshiva University, USA
Mikhail Pletnikov, Johns Hopkins 
University, USA
*Correspondence:
Ming D. Li, Department of Psychiatry 
and Neurobehavioral Sciences, 
University of Virginia, 1670 Discovery 
Drive, Suite 110, Charlottesville, VA 
22911, USA.
e-mail: ming_li@virginia.eduFrontiers in Psychiatry  | Molecular Psychiatry    March 2011  | Volume 2  | Article 5  |  2
Wang et al.  Effect of nicotine on neuronal genes
rnA IsolAtIon
Total RNA was isolated separately from each of the drug-treated 
and control cultures using Trizol (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. To eliminate potential 
residual DNA contamination, the RNA samples were treated with 
RNase-free DNase I at 37°C for 30 min followed by inactivation 
at 65°C for 10 min. The RNA concentration of each sample was 
measured at an optical density of 260 nm, and the integrity of the 
RNA was checked by examination of 28S and 18S ribosomal bands 
using agarose–formaldehyde gel electrophoresis.
MIcroArrAy productIon
A pathway-focused oligoarray designed specifically for the study 
of drug addiction and related disorders was used. Briefly, 3,565 
genes essential to CNS activities for the maintenance of neuronal 
homeostasis, as well as those associated with the neuron response 
to addictive substances such as nicotine, alcohol, and cocaine, were 
selected on the basis of an earlier version of a pathway-focused 
cDNA microarray (Konu et al., 2004a) and an extensive literature 
survey. These genes covered most of the major pathways related 
to cell metabolism, genetic information processing, cellular sign-
aling transduction, neuron-related disease, and cell communica-
tion. OligoWiz1 was used to design the oligonucleotide for each 
gene. The average length of these oligonucleotides was 59.2 ± 3.8 
bases (mean ± SD), with a GC content of 0.53 ± 0.05 and a Tm 
of 76.4 ± 1.7°C. The oligonucleotides and 10 control clones were 
synthesized by SIGMA Genosys (Sigma-Aldrich, St. Louis, MO, 
USA) and spotted at a concentration of 40 μM in 3× SSC and 1.5 M 
betaine buffer onto CMT-GAPS II slides (Corning Life Sciences, 
Lowell, MA, USA) using an OmniGrid MicroArrayer OGR-03 
(GeneMachines, San Carlos, CA, USA).
cdnA probe lAbelIng, hybrIdIzAtIon, And scAnnIng
To reduce the potential influence of any gene-specific dye effect, a 
universal reference design was used in the microarray analysis. For 
each experimental group, six independent cultures were prepared. 
Another 12 independent control cultures were used as “universal 
controls.” For each sample, 10 μg of total RNA was extracted for 
cDNA synthesis. Following purification with phenol:chloroform 
extraction and isopropanol precipitation, total RNA was dissolved 
in 28 μl of water, mixed with 4 μl of 10× buffer, 4 μl of 10 mM dTTP-
free dNTP, 1 μl of 10 mM dTTP, 2 μl of 1 mM cyanine 3-dUTP (for 
either nicotine-treated or control sample) or cyanine 5-dUTP (for 
universal control sample; Enzo, Farmingdale, NY, USA), and 1 μl 
of Klenow fragment (50 units/μl), then incubated at 37°C for 3 h 
prior to purification with a QIAquick PCR kit (Qiagen, Valencia, 
CA, USA). The cyanine 3-labeled sample (either nicotine-treated 
or control) cDNA probes were mixed with the cyanine 5-labeled 
universal control cDNA probe and added to 7.5 μl of 20× SSC, 3 μg 
of CotI DNA, 3 μg of polyA, and 0.5 μl of 10% SDS adjusted to 
a final volume of 50 μl. The mixture was applied to the pathway-
focused oligonucleotide microarray and hybridized overnight at 
60°C. Slides were washed in 1× SSC and 0.2% SDS at 60°C for 5 min 
followed by washing in 0.1× SSC and 0.2% SDS and in 0.1× SSC at 
room temperature for 10 min each. Hybridized slides were scanned 
  cytoskeleton-associated protein (ARC) and dendrin in specific 
brain regions of rats (Schochet et al., 2005, 2008; Schmitt et al., 
2008). Acute nicotine exposure not only increases the activity of 
dopaminergic neurons and promotes dopamine release (Levin and 
Rose, 1995), but also enhances dopamine turnover and metabolism 
(Grenhoff and Svensson, 1988). The administration of a single dose 
of nicotine enhances the synthesis and release of striatal dynorphin, 
a component of the circuit promoting negative motivational and 
affective states, possibly under the regulation of dopamine and 
glutamate (Isola et al., 2009). Acute nicotine exposure may impair 
nNOS-dependent dilation of cerebral arterioles via a mechanism 
related to the increase in oxidative stress (Arrick and Mayhan, 
2007). Even a few minutes of nicotine exposure can significantly 
suppress arachidonic acid signaling in various brain regions in 
rats (Chang et al., 2009). In mice, acute administration of a low 
dose of nicotine increases phosphor-ERK1/2 immunoreactivity in 
the NAc, prefrontal cortex, and some other regions innervated by 
the mesolimbic dopamine pathway (Barik and Wonnacott, 2009).
Clearly, acute nicotine exposure can evoke multiple effects in the 
neuronal system, but its action mechanism is not completely under-
stood. The neuron-like human neuroblastoma cell line SH-SY5Y 
endogenously expresses various nAChR subunits (e.g., α3, α5, 
α7, β2, and β4; Gould et al., 1992; Peng et al., 1994), which are 
assembled to form different types of nAChRs, such as α3
*-nAChR 
or homomeric α7-nAChR receptors. The cells therefore provide 
a suitable in vitro model to investigate alterations in nAChRs in 
the presence of cholinergic ligands and have been widely used in 
  nicotine-related study. In an earlier study, 17 genes with diverse 
biological functions were found to be significantly regulated in 
SH-SY5Y cells after exposed to 1 mM nicotine for 1 h (Dunckley 
and Lukas, 2003). The authors further showed that most of these 
genes were regulated via nAChRs-mediated mechanisms. However, 
because of the limitation of array technologies and bioinformatics 
tools at that time, a detailed analysis, especially at the biological 
pathway level, was impossible. With the rapid progress in the fields 
of genomics and bioinformatics, a detailed and comprehensive 
profiling of the genes and pathways responsive to acute nicotine 
treatment becomes feasible and necessary. In this study, by using 
an established and well-tested in vitro model in the field, we inves-
tigated the relation between acute nicotine exposure and neuronal 
function by examining the genes and biochemical pathways differ-
entially regulated by nicotine in SH-SY5Y cells using a customized 
pathway-focused microarray (Cao et al., 2011; Wei et al., 2011).
MAterIAls And Methods
cell culture And drug treAtMent
The human neuroblastoma SH-SY5Y cells were purchased from 
the American Type Culture Collection (ATCC; Manassas, VA, USA) 
and cultured in a 1:1 mixture of ATCC-formulated Eagle’s Minimal 
Essential Medium and F12 medium supplemented with 10% fetal 
bovine serum (GIBCO Invitrogen, Grand Island, NY, USA) at 37°C 
in a humidified atmosphere of 5% CO2. At about 80% confluence, 
cells were treated with 1 mM nicotine (calculated as free base), 3 μM 
mecamylamine (nicotinic receptor antagonist), 1 mM nicotine in 
combination with 3 μM mecamylamine, or no drug (controls) for 
1 h. For each experimental group, six independent cultures were 
prepared (N = 6). 1http://www.cbs.dtu.dk/services/OligoWiz/www.frontiersin.org  March 2011  | Volume 2  | Article 5  |  3
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was done as described previously (Gutala et al., 2004; Konu et al., 
2004a). Briefly, PCR was carried out in a volume of 25 μl using the 
TaqMan assay on the ABI 7000 Sequence Detection System. The 18S 
ribosomal RNA was used as an internal control to normalize the 
expression patterns of target genes. Data analysis was performed 
using a comparative Ct method (Winer et al., 1999). Five independ-
ent cell cultures were prepared under the same conditions used for 
the microarray experiments for both the nicotine treatment and 
control groups (N = 5).
Western blotting analysis
The protein concentration of MAPK14 (p38) was measured in 
both nicotine-treated (1 mM for 1 h) and control samples. After 
appropriate treatment, cells were harvested using RIPA buffer fol-
lowed by incubation on ice for 30 min. The cells were centrifuged 
at 12,000×g for 15 min to remove debris, and the total protein con-
tent of the lysates was determined using the Bio-Rad protein assay 
(Bio-Rad, Chicago, IL, USA). The samples were boiled at 90°C for 
5 min and then cooled on ice. Twenty micrograms of protein was 
fractionated on 10% SDS-polyacrylamide gel (containing 30% 
acrylamide and 0.8% bisacrylamide) in Tris–  glycine buffer con-
taining SDS at 80 V for approximately 1.5 h. The separated proteins 
were then transferred to a PVDF membrane (Millipore, Bedford, 
MA, USA) overnight at 30 V at 4°C. The membrane was blocked 
for 1 h at room temperature with 5% non-fat dry milk diluted 
in TBST buffer and incubated overnight with primary antibody 
at 4°C. After being washed three times in TBST, the membranes 
were subjected to secondary antibody conjugated to horseradish 
peroxidase for 1 h at room temperature. Immunoreactivity was 
detected using an enhanced chemiluminescence kit (Bio-Rad), 
and the preparations were exposed to X-ray film. The MAPK14 
antibody was from Calbiochem (San Diego, CA, USA), and anti-
α-tubulin monoclonal antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) was used to detect the housekeeping protein 
α-tubulin. The MAPK14 immunoreactivity bands were quan-
tified using densitometry. After the films were developed, they 
were scanned on a Microtek ScanMaker i800 (Microtek Lab Inc., 
Cerritos, CA, USA) with ScanWizard 5.5 at a resolution of 600 
dpi for quantitative analysis with ImageQuant 5.1 (Molecular 
Dynamics, Sunnyvale, CA, USA). The relative MAPK14 values were 
normalized to α-tubulin, and the significance of the difference 
between the nicotine-treated and control samples was determined 
by t-test via MATLAB (The Mathworks, Natick, MA, USA). Four 
independent cell cultures were prepared under the same conditions 
used for the microarray experiments for both nicotine treatment 
and control groups (N = 4).
results
gene expressIon chAnges In response to Acute nIcotIne 
exposure
In the nicotine-treated group, 295 genes were significantly modu-
lated (p < 0.05; Table A1 in Appendix), with FDR values ≤0.258. 
Among these genes, 98 had p-values <0.01, which corresponded to 
an FDR value of 0.155. Of the 295 differentially expressed genes, 221 
showed no significant changes (p ≥ 0.05) in the cells treated with 
nicotine and mecamylamine, suggesting these genes were regulated 
through the mecamylamine-modulated nicotinic receptors.
using the ScanArray Gx microarray scanner, and the intensities of 
each probe were quantified with the ScanArray Express microarray 
analysis system (PerkinElmer, Waltham, CA, USA).
dAtA norMAlIzAtIon And stAtIstIcAl AnAlysIs
After  scanning  the  arrays,  we  obtained  the  raw  hybridization 
intensity for each element printed on the array and then used the 
background-subtracted median intensity of each spot for further 
statistical analysis. The two replicates on each chip were initially 
processed separately. The weakest 5% of spots and the saturated 
spots in each replicate were discarded. An intensity-dependent 
method, locally weighed linear regress (Lowess), was used to nor-
malize the data of each replicate (Yang et al., 2002). To minimize 
experimental error, genes with six or fewer valid measurements 
were removed from further analysis, and the two technical replicates 
per chip were averaged to obtain the measurement of each gene 
for a given sample. The normalized data from each drug treat-
ment group were compared with the normalized data of controls, 
and significantly regulated genes were identified by unpaired two-
tailed Student’s t-test. To control the multiple comparison error, 
the false discovery rate (FDR) was calculated by the method of 
Benjamini and Hochberg (1995) via MATLAB (The Mathworks 
Inc., Natick, MA, USA).
The genes significantly regulated by each drug treatment were 
analyzed by ingenuity pathway analysis (IPA)2 with the goal of 
revealing the enriched biochemical pathways. The core of IPA is 
the ingenuity pathways knowledge base (IPKB), which contains the 
biological function, interaction, and other related information of 
a curated gene set and more than 330 biochemical pathways. This 
pathway-based software is designed to identify global canonical 
pathways, dynamically generated biological networks, and global 
functions from a given list of genes. Basically, the genes with their 
symbols, corresponding GenBank Accession Numbers, or both were 
uploaded into the IPA and compared with the genes included in 
each canonical pathway using the whole gene set of IPKB as the 
background. All the pathways with one or more genes overlapping 
the candidate genes were extracted. In IPA, each of these pathways 
was assigned a p-value, which denoted the probability of overlap 
between the pathway and input genes, via Fisher’s exact test. Because 
a relatively large number of pathways were examined, multiple 
comparison correction for the individually calculated p-values was 
necessary to make reliable statistical inferences. The FDR was again 
calculated with the method of Benjamini and Hochberg (1995).
Quantitative real-time RT-PCR
The quantitative real-time RT-PCR (qRT-PCR) was carried out 
for eight representative genes selected from the aforementioned 
differentially expressed genes: cyclin d3 (CCND3), cell division 
cycle 42 (CDC42), death domain-associated protein 6 (DAXX), 
mitogen-activated protein kinase 14 (MAPK14), mads box tran-
scription enhancer factor 2, polypeptide D (MEF2D), nerve growth 
factor receptor (NGFR), phospholipase A2, group IVA (PLA2G4A), 
and transformation-related protein 53 (TRP53). All primers and 
TaqMan probes for the eight genes were purchased from Applied 
Biosystems (ABI, Foster City, CA, USA), and qRT-PCR analysis 
2https://analysis.ingenuity.comFrontiers in Psychiatry  | Molecular Psychiatry    March 2011  | Volume 2  | Article 5  |  4
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treatment group, suggesting that mecamylamine may have either 
no significant effect or a synergistic effect with nicotine on the 
expression changes in these genes.
pAthwAys enrIched In the genes regulAted by nIcotIne
As shown above, genes and biological processes involved in different 
functions were regulated by nicotine exposure. To further identify 
the biological themes underlying these genes, the biochemical path-
ways enriched in the nicotine-regulated genes were investigated. 
Two sets of genes were analyzed by IPA; i.e., those regulated signifi-
cantly by 1 h of nicotine exposure (N = 295), and those with expres-
sion significantly changed by 1 h of nicotine with the effect being 
blocked by mecamylamine (N = 221). The second gene set included 
only those with p-values ≥0.05 during co-treatment with nicotine 
and mecamylamine. Although in this set, some genes may have 
considerable fold changes, the selection was based on p-value only.
Results from IPA analysis showed that 14 pathways were signifi-
cantly enriched among the genes regulated by nicotine (p < 0.05; 
FDR < 0.05; Figure 1; Table 1), and 13 pathways were enriched in 
the second gene set. Among these pathways, nine were identified for 
both gene sets; i.e., glucocorticoid receptor signaling, p38 MAPK 
signaling,  PI3K/AKT  signaling,  PTEN  signaling,  acute-phase 
response signaling, ERK/MAPK signaling, Toll-like receptor sign-
aling, VEGF signaling, and T-cell receptor signaling. For the gene 
set regulated by nicotine treatment, five pathways were uniquely 
identified; i.e., mitochondrial dysfunction, PPAR signaling, IL-6 
signaling, hepatic fibrosis/hepatic stellate cell activation, and death 
receptor signaling. The pathways uniquely identified in the second 
gene set were CD28 signaling in T-helper cells, CD40 signaling, role 
of NFAT in regulation of the immune response, and IL-8 signaling. 
Of the 295 genes, 128 were down-regulated by acute nicotine 
exposure. These included multiple transcription factors; e.g., acti-
vating transcription factor 2 (ATF2), general transcription factor 
IIH polypeptide 2 (GTF2H2), nuclear respiratory factor 1 (NRF1), 
and transcription factor EB (TRFEB). A few genes related to cell 
adhesion were also down-regulated by acute nicotine exposure; e.g., 
ninjurin 1 (NINJ1), kit ligand (KITLG), integrin beta 1 (ITGB1), 
neurexin 1 (NRXN1), and laminin gamma 1 (LAMC2). Some cell 
cycle-related genes were suppressed; e.g., cell division cycle 14 
homolog B (CDC14B), cell division cycle 2 homolog A (CDC2A), 
cell division cycle 42 homolog (CDC42), G1 to S phase transition 
1 (GSPT1), and meiotic recombination 11 homolog A (MRE11A).
The remaining 167 differentially expressed genes were up-regulated 
by nicotine treatment. Genes included in this category included those 
related to: (a) mitochondrial electron transport; e.g., cytochrome 
c oxidase, subunit VIIC (COX7C), polypeptide 1 of cytochrome 
p450 family 17 subfamily A (CYP17A1), rieske iron–sulfur protein 
(RISP), and NADH dehydrogenase (ubiquinone) flavoprotein 1 
(NDUFV1); (b) ubiquitination; e.g., ubiquitin-activating enzyme E1 
Chr X (UBE1X), ubiquilin 1 (UBQLN1), ubiquitin-specific protease 
28 (USP28), and ubiquitin-conjugating enzyme e2a (UBE2A); and 
(c) transport; e.g., potassium channel TWIK (KCNK1), nucleotide-
sensitive chloride channel 1A (CLNS1A), T type alpha 1G subunit of 
voltage-dependent calcium channel (CACNA1G), solute carrier fam-
ily 8 (sodium/calcium exchanger) member 2 (SLC8A2), and solute 
carrier family 2 (facilitated glucose transporter) member 4 (SLC2A4).
Of the 295 genes significantly regulated by nicotine treatment, 
74 were differentially expressed (p < 0.05) in the cells treated with 
nicotine + mecamylamine (Table A1 in Appendix). Most of these 
genes showed the same trend of regulation as those in the nicotine 
Figure 1 | Pathways significantly enriched in the genes differentially regulated by nicotine exposure. The p-values are shown in negative logarithm form at 
base 10. The dashed line indicates the threshold corresponding to p = 0.05. All 14 pathways shown have an FDR < 0.05.www.frontiersin.org  March 2011  | Volume 2  | Article 5  |  5
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pathways were assigned p-values <0.05, they are not reported here 
because of the relatively high FDR value after multiple comparison 
correction (with the minimum FDR being 0.262).
As shown in Table 1, multiple genes in each pathway were sig-
nificantly regulated by nicotine exposure. Although the expression 
changes of some genes within each pathway were not statistically 
significant, they showed consistent patterns with those signifi-
cantly modulated. One of the pathways, p38 MAPK signaling, is 
shown in Figure 2. Genes involved in this pathway were exten-
sively regulated in response to nicotine exposure. The expression 
In the pathways identified for the two gene sets, the genes affected 
were not identical (Table 1). For the nicotine + mecamylamine-
treated samples, the pathways included only genes whose expression 
was modulated by nicotine exposure but blocked by simultaneous 
treatment with the two chemicals. For the nicotine-treated samples, 
the pathways also included genes whose expression was modulated 
in both nicotine- and nicotine + mecamylamine-treated samples.
We  also  performed  pathway  analysis  on  the  74  genes  sig-
nificantly  regulated  in  both  nicotine-treated  and  the  nico-
tine + mecamylamine-treated samples via IPA. Although a few 
Table 1 | Pathways enriched in genes significantly regulated by nicotine and genes significantly regulated by nicotine but not by 
nicotine + mecamylamine.
  gene regulated  gene regulated 
  by nicotine  by nicotine but 
    blocked by NM*
Pathway p-Value FDr p-Value FDr genes significantly regulated by nicotine in the pathway**
Glucocorticoid receptor 
signaling
3.11 × 10−7 1.77 × 10−4 4.46 × 10−6 7 .00 × 10−4 AGT, AR, BCL2, CD3G, DUSP1(MKP1), FGG, FOS, gTF2H2, IKBKG, 
JAK3, MAP3K7IP1(TAB1), MAPK14, MED14, NFATC3, PIK3CG, 
SMAD2, STAT5A, TgFB2, TGFBR2, TRAF6, YWHAH
p38 MAPK signaling 2.40 × 10−6 6.82 × 10−4 6.54 × 10−5 2.57 × 10−3 ATF2, DAXX, DUSP1(MKP1), HMGN1, IRAK3, MAP3K7IP1(TAB1), 
MAPK14, MEF2D, PLA2G4A, TgFB2, TGFBR2, TRAF6
PI3K/AKT signaling 9.55 × 10−6 1.81 × 10−3 3.29 × 10−5 1.7 × 10−3 BCL2, EIF4EBP1, FOXO1, IKBKG, ITGB1, JAK3, PIK3CG, PPM1L, 
rPS6KB1, SFN, TrP53, YWHAH
PTEN signaling 5.01 × 10−5 7 .13 × 10−3 1.51 × 10−3 0.030 BCL2, BCL2L11, CDC42, FOXO1, IKBKG, ITGB1, NgFr, PIK3CG, 
rPS6KB1, YWHAH
Acute-phase response 
signaling
1.02 × 10−4 0.012 7 .06 × 10−4 0.018 AGT, APOA1, FGG, FOS, IKBKG, IL6R, IL6ST, MAP3K7IP1(TAB1), 
MAPK14, NgFr, PIK3CG, TF, TRAF6
ERK/MAPK signaling 1.70 × 10−4 0.015 2.51 × 10−4 0.016 ArAF, ATF2, DUSP1, EIF4EBP1, FOS, ITGB1, PIK3CG, PLA2G4A, 
PPM1L, PPP1CA, RAPGEF3, YWHAH
Mitochondrial 
dysfunction
2.09 × 10−4 0.015 – – COX6B1, COX7B, COX7C, NDUFA4, NDuFV1, OGDH, SDHB, SDHC, 
SNCA, UQCRFS1
VEGF signaling 2.14 × 10−4 0.015 6.17 × 10−4 0.018 BCL2, EIF2B1, eiF2B5, FOXO1, PIK3CG, SFN, VCL, VEGFA
Toll-like receptor 
signaling
2.57 × 10−4 0.015 2.94 × 10−3 0.045 FOS, IKBKG, IRAK3, MAP3K7IP1(TAB1), MAP4K4, MAPK14, TRAF6
PPAR signaling 2.75 × 10−4 0.015 – – FOS, IKBKG, MAP3K7IP1(TAB1), MAP4K4, NgFr, NR2F1, STAT5A, 
TRAF6
IL -6 signaling 2.95 × 10−4 0.015 – – FOS, IKBKG, IL6R, IL6ST, MAP3K7IP1(TAB1), MAP4K4, MAPK14, 
NgFr, TRAF6
T-cell receptor signaling 5.13 × 10−4 0.024 3.97 × 10−4 0.013 CALM2, CD3G, CSK, FOS, IKBKG, NFATC3, PIK3CG, ZAP70
Hepatic fibrosis/hepatic 
stellate cell activation
7 .24 × 10−4 0.032 – – AGT, BCL2, IGF1R, IL6R, NgFr, SMAD2, TgFB2, TGFBR2, VEGFA
Death receptor signaling 8.71 × 10−4 0.035 – – BCL2, CFLAR, DAXX, IKBKG, MAP4K4, TNFRSF10B
CD28 signaling in 
T-helper cells
– – 2.90 × 10−5 1.72 × 10−3 ARPC1A, ARPC1B, CALM2, CD3G, CDC42, CSK, FOS, IKBKG, 
NFATC3, PIK3CG, ZAP70
CD40 signaling – – 1.38 × 10−3 0.030 FOS, IKBKG, JAK3, MAP2K5, MAPK14, PIK3CG, TRAF6
Role of NFAT in 
regulation of the 
immune response
– – 3.01 × 10−3 0.045 CALM2, CD3G, FOS, GNA15, IKBKG, MEF2D, NFATC3, PIK3CG, 
ZAP70
IL -8 signaling – – 3.15 × 10−3 0.045 BCL2, CCND3, EIF4EBP1, IKBKG, IRAK3, LIMK1, PIK3CG, TRAF6, 
VEGFA
*NM, nicotine + mecamylamine. **For each pathway, all the genes were significantly regulated by nicotine exposure (p < 0.05). The expression changes of the genes 
were blocked by the co-treatment of nicotine + mecamylamine except those shown in bold font, which means genes shown in bold font were differentially expressed 
in both the nicotine and nicotine + mecamylamine-treated samples.Frontiers in Psychiatry  | Molecular Psychiatry    March 2011  | Volume 2  | Article 5  |  6
Wang et al.  Effect of nicotine on neuronal genes
Figure 3 shows the fold change in activity along with the stand-
ard deviation of the eight genes in response to nicotine treatment 
relative to the controls, as detected by microarray and quantitative 
RT-PCR. These analyses revealed significant up-regulation of seven 
genes and down-regulation of CDC42, which is consistent with the 
result from the microarray analysis. Furthermore, a comparison 
of the fold changes of each gene detected by the two molecular 
techniques revealed a correlation coefficient of 0.87 (p = 0.0068), 
indicating overall measurement of gene expression from the two 
approaches  was  consistent. Although  only  eight  representative 
genes were selected for verification by qRT-PCR, a comparison of 
the two techniques demonstrates that the results from our microar-
ray analyses were highly reproducible and reliable.
Furthermore, we used Western blotting to determine the total 
amount of MAPK14 (p38 MAPK) protein in lysates of cells treated 
with 1 mM nicotine and control samples. The results revealed sig-
nificant induction (35.5%; p = 0.03) of MAPK14 expression in 
nicotine-treated samples (Figure 4).
dIscussIon
In this study, we profiled gene expression in the SH-SY5Y cell line 
in response to 1 h of 1 mM nicotine exposure using a pathway-
focused oligonucleotide microarray. Treatment with 1 mM nico-
tine maximally induces the up-regulation of numbers of nAChR 
  radioligand-binding sites in SH-SY5Y cells, and this up-regulation 
of a few genes, such as DAXX, MKP1/5, MAPK14, and MEF2, was 
significantly modulated by acute nicotine exposure (p < 0.05). 
Although the expression of other genes; e.g., ASK1, MKK4, and 
HPK1, was not significantly regulated under the experimental con-
ditions, they showed patterns consistent with those of significantly 
regulated genes.
Expression verification of representative genes
In an independent experiment involving the same treatments as 
in the microarray analysis, qPCR was performed on eight repre-
sentative genes; i.e., CCND3, CDC42, DAXX, MAPK14, MEF2D, 
NGFR, PLA2G4A, and TRP53. All these genes were significantly 
regulated by nicotine exposure (Table A1 in Appendix), and 
each gene was part of one or more enriched pathways associated 
with nicotine treatment (Table 1). For example, CCND3 is part 
of the IL-8 signaling pathway; CDC42 of CD28 signaling and 
PTEN signaling pathways; DAXX of the p38 MAPK signaling 
pathway; MAPK14 of multiple pathways such as glucocorticoid 
receptor signaling, p38 MAPK signaling, acute-phase response 
signaling, and Toll-like receptor signaling; MEF2D of p38 MAPK 
signaling that plays a role of NFAT in regulation of the immune 
response; NGFR of PTEN signaling, acute-phase response sig-
naling, PPAR signaling, and IL-6 signaling; PLA2G4A of p38 
MAPK and ERK/MAPK signaling; and TRP53 of the PI3K/AKT 
signaling pathway.
Figure 2 | gene expression pattern of the P38 MAPK signaling pathway. 
Genes shown in green are down-regulated, whereas those shown in red are 
induced by acute nicotine treatment. The genes significantly regulated by 
nicotine are those with closed blue edges. To demonstrate the expression 
pattern of the pathway, all the genes with expression ratios >1.1 or <0.90 
relative to the controls are also shown. The genes in white with light gray edges 
are either not regulated by nicotine (expression ratios between 0.9 and 1.1) or 
were not measured in our analysis. The pathway was drawn by the IPA program.www.frontiersin.org  March 2011  | Volume 2  | Article 5  |  7
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has been implicated in the long-lasting effects of nicotine exposure, 
such as dependence and tolerance (Ke et al., 1998; Dunckley and 
Lukas, 2003, 2006). Given that the purpose of this study was to 
determine the pharmacologic effects of nicotine using an in vitro 
system, we adopted a 1-mM concentration for nicotine, as used in 
a previous study (Dunckley and Lukas, 2003). However, the current 
study is neither a simple modeling of the physiological conditions 
of smokers, nor repeat earlier studies in the same model. Instead, it 
focuses on exploring the molecular response at the pathway level 
to acute nicotine exposure that may maximally activate the func-
tion of molecules such as nAChRs and their downstream genes in 
SH-SY5Y cells.
Nicotine  evokes  its  physiological  effects  mainly  by  bind-
ing with nAChRs. As a broad-spectrum antagonist of nAChRs, 
mecamylamine at a concentration of 3 μM can block most of the 
responses of α3*-nAChR to nicotine, as well as a fraction of the 
α7-nAChR responses (Chavez-Noriega et al., 1997; Papke et al., 
2001; Dunckley and Lukas, 2003, 2006). Of the 295 genes signifi-
cantly regulated by nicotine, 221 were not differentially expressed 
during co-treatment of nicotine + mecamylamine, providing evi-
dence of direct involvement of nAChR in the process of modu-
lation of SH-SY5Y cells by nicotine. Thus, our results indicate 
that the changes in 75% (221/295) of the differentially expressed 
genes in response to nicotine are attributable to direct interaction 
with nAChRs, especially α3*-nAChR receptors, which is consist-
ent with the conclusions drawn from previous studies (Dunckley 
and Lukas, 2003, 2006). However, it is difficult to confirm a clear 
relation between nicotinic receptor subtype and gene expression 
from our findings because of the existence of different subtypes 
of nAChRs on the membrane of SH-SY5Y cells. These receptors 
have different properties, such as sensitivity to nicotine, perme-
ability to calcium, and propensity to desensitize. It is possible that 
the regulation of some genes is related to multiple subtypes of 
nAChRs, including those α3- or α7-containing receptors. Partially 
blocking the function of some types of receptors (e.g., α3*- and 
α7-containing) may reduce the overall activation of nAChRs, which 
may lead to more subtle regulation of some genes compared with 
the response when mecamylamine is not applied. On the other 
hand, our results do not imply that nAChRs play little or no role 
in the regulation of genes significantly regulated in both nicotine 
and nicotine + mecamylamine treatment. The expression changes 
of these genes may have multiple explanations. A small fraction of 
α3*-nAChR receptors remain functionally active under the influ-
ence of mecamylamine, which may be sufficient to regulate the 
expression of some genes. At the same time, α7 and other types 
of nAChR receptors may be responsible for the expression change 
of some other genes as well. It is also possible that the expression 
changes of some genes in response to nicotine are caused by mecha-
nisms not directly involving nAChRs, as nicotine can readily cross 
the plasma membrane and affect intracellular processes through 
an nAChR-independent mechanism.
Our analysis showed that acute nicotine exposure has effects on the 
expression of a large number of genes with diverse functions (Table A1 
in Appendix). Among them are genes involved in the ubiquitin–pro-
teasome pathway, such as proteasome subunit beta 4 (PSMB4), pro-
teasome 26S subunit non-ATPase 2 (PSMD2),   ubiquitin-activating 
enzyme E1 Chr X (UBE1X),   ubiquitin-conjugating enzyme E2A 
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Figure 3 | Comparative plot of results from microarray and real-time 
rT-PCr verification for eight representative genes. Y axis represents the 
fold change of expression in 1-h nicotine-treated SH-SY5Y cells compared with 
the average expression in the control sample for that particular gene. For the 
qRT-PCR results, the expression of each gene was normalized to the average 
of control samples. Abbreviations: CCND3, cyclin D3; CDC42, cell division 
cycle 42 homolog; DAXX, Fas death domain-associated protein; MAPK14, 
mitogen-activated protein kinase 14; MEF2D, myocyte enhancer factor 2d; 
NGFR, nerve growth factor receptor; PLA2G4A, phospholipase A2, group IVA; 
TRP53, transformation-related protein 53.
Figure 4 | expression of MAPK14 (p38 MAPK) protein in SH-SY5Y cells 
determined by Western blotting. The SH-SY5Y cells were treated for 1 h 
with or without (Controls) 1 mM nicotine. After treatment, protein was purified 
from the lysates and analyzed by Western blotting. In this figure, the MAPK14 
concentration was determined using a specific monoclonal antibody. The 
histogram shows the relative expression of MAPK14 normalized to expression 
of α-tubulin, which demonstrated that the protein concentrations in 
nicotine-treated cells are significant higher than those in controls (p < 0.03). 
Data are presented as mean ± SEM (N = 4).Frontiers in Psychiatry  | Molecular Psychiatry    March 2011  | Volume 2  | Article 5  |  8
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(NRXN1) was down-regulated in both treatment groups. This and 
another member of the same family, NRXN3, were associated with 
smoking behaviors in several recent genetic studies (Bierut et al., 
2007; Nussbaum et al., 2008; Novak et al., 2009). Although our 
data provide no further information on the mechanisms by which 
these genes are regulated, it is clear that acute nicotine exposure is 
responsible for their expression changes.
Consistently, the pathways enriched in nicotine-regulated genes 
were involved in many biological processes, such as neural devel-
opment/synaptic plasticity, cell survival/death, immune response, 
and cellular metabolism. Of the identified pathways, nine were 
enriched in genes significantly regulated by nicotine, as well as those 
regulated by nicotine but blocked by mecamylamine, indicating 
these pathways were regulated mainly through nAChR-dependent 
mechanisms. Among these pathways, acute-phase response sign-
aling, Toll-like receptor signaling, and T-cell receptor signaling 
play important roles in the immune response. Although the other 
pathways; i.e., glucocorticoid receptor signaling, p38 MAPK signal-
ing, PI3K/AKT signaling, PTEN signaling, ERK/MAPK, and VEGF 
signaling, are involved in a large range of physiological processes, all 
of them represent key pathways for maintaining proper neuronal 
functions, such as cellular signaling and proliferation and differ-
entiation of neurons. The modulation of the neuronal function-
related pathways may have relatively long-lasting consequences. 
One example is that adolescent rats display different long-term 
neuroadaptive responses to acute nicotine than do adult animals, 
which is suggested to be related to the immature or still-developing 
plasticity mechanisms in the prefrontal cortex of young animals 
(Schochet et al., 2004). Among these pathways, particularly inter-
esting are the glucocorticoid receptor and p38 MAPK signaling.
For the glucocorticoid receptor signaling pathway, 21 genes were 
significantly regulated by acute nicotine treatment (Table 1). The 
glucocorticoid receptor, GCCRα (also known as nuclear receptor 
subfamily 3, group c, member 1; NR3C1) was slightly suppressed by 
nicotine (fold change 0.83; p-value = 0.09). The regulation of these 
genes clearly indicates that the glucocorticoid receptor signaling path-
way is modulated by acute nicotine exposure. Glucocorticoids, cortisol 
in humans, and corticosterone in the rodent, are secreted by the adrenal 
cortex and belong to the family of steroid hormones. Glucocorticoids 
and their receptors are essential for the development and survival of 
vertebrates (Cole et al., 1995). All the cellular responses to glucocor-
ticoids are attributed to their binding to the intracellular glucocor-
ticoid receptor (GCCR) and the translocation of the complexes to 
the nucleus, which then modulates gene expression through diverse 
mechanisms (Dittmar et al., 1997, 1998; Robinson-Rechavi et al., 
2001). Although the activity of the GCCR is directly related to gene 
transactivation, considerable cross-talk occurs between the GCCR and 
a cohort of molecules to mediate their functions as transcriptional 
regulators. Studies on animals and humans have outlined the impor-
tance of glucocorticoids in mediating drug-seeking behavior and the 
rewarding properties of psychostimulant drugs (Piazza and Le Moal, 
1997; Marinelli and Piazza, 2002). For example, in mice, activation of 
glucocorticoid receptors increases the propensity to self-administer 
cocaine by acting on the postsynaptic dopaminoceptive neurons of 
the dopaminergic system (Ambroggi et al., 2009). It was also found 
that learning and memory deficits in cocaine-dependent humans are 
associated with higher cortisol concentrations (Fox et al., 2009). The 
(UBE2A), ubiquilin 1 (UBQLN1), and ubiquitin-  specific protease 28 
(USP28). Earlier studies showed that genes involved in the ubiqui-
tin–proteasome pathway were regulated in SH-SY5Y cells by 1 mM 
nicotine after both 1- and 24-h treatment (Dunckley and Lukas, 
2003, 2006). In the current study, more genes related to this pathway 
were found to be modulated by nicotine exposure. The ubiquitin–
proteasome pathway is regulated by   nicotine in cell lines (Konu 
et al., 2004b; Ficklin et al., 2005; Wang et al., 2007), animal models 
(Kane et al., 2004; Li et al., 2004; Rezvani et al., 2007; Vadasz et al., 
2007; Wang et al., 2009), and human smokers (Mexal et al., 2005). 
Thus, the changes in ubiquitin–proteasome-related genes observed 
in this study may not be specific for the relatively high nicotine 
concentration; instead, they may be caused by mechanisms similar 
to those discovered in previous studies.
Multiple genes involved in mitochondrial functions also were 
found to be regulated by nicotine; these include acyl-coenzyme A 
thioesterase 3 (ACATE3), ATP synthase subunit g (ATP5L), mito-
chondrial ribosomal protein S7 (MRPS7), NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex 4 (NDUFA4), and RISP. Previous 
studies have demonstrated that nicotine exposure can modulate 
the morphology (Onal et al., 2004) and function of mitochondria, 
such as protein turnover (Katyare and Shallom, 1988), enzyme 
activity (Xie et al., 2005), and generation of reactive oxygen species 
(Cormier et al., 2001; Soto-Otero et al., 2002). Recently, we showed 
that nicotine exposure regulates the electron transport system in 
multiple brain regions of rats (Wang et al., 2009). The results from 
the current study indicate that acute nicotine exposure also can 
regulate the expression of mitochondrial genes, potentially lead-
ing to the modulation of mitochondrial functions. In addition, 
several genes involved in synaptic transmission were identified, 
such as neuron-specific gene family member 1 (NSG1), synuclein 
alpha (SNCA), synapsin 2 (SYN2), synaptotagmin 2 (SYT2), syn-
aptotagmin 7 (SYT7), and tachykinin 2 (TAC2). The expression 
of NSG1 in mouse cortical neurons is regulated by treatment with 
nicotine, alcohol, or both (Wang et al., 2007). SNCA is suggested as a 
candidate associated with alcohol, cocaine, and methamphetamine 
dependence (Kobayashi et al., 2004; Bonsch et al., 2005; Mash et al., 
2008; Spence et al., 2009). The phosphorylation of synapsin is regu-
lated by cocaine in a region-specific manner in rat brain (Edwards 
et al., 2007). The regulation of these synaptic transmission-related 
genes indicates that even a short nicotine exposure may have impor-
tant effects on neuronal functions.
Among the 74 genes significantly regulated by both nicotine 
and nicotine + mecamylamine treatment, some have already been 
reported to be involved in the cellular response to nicotine exposure. 
Activating transcription factor 2 (ATF2), a DNA-binding protein 
that binds to cAMP response elements, was suppressed in both 
treatment conditions and is involved in mediating the activation 
of tyrosine hydroxylase transcription under nicotine treatment in 
PC12 cells (Gueorguiev et al., 2006). Nerve growth factor (NGF), 
a member of the neurotrophin family, is an essential mediator of 
neuronal activity and synaptic plasticity (Levi-Montalcini, 1987; 
Thoenen et al., 1987). Both NGF and its receptor, NGFR, were up-
regulated in the two treatment groups. Nicotine has been reported 
to regulate the expression of NGF and NGFR in cell lines or tis-
sues (Terry and Clarke, 1994; Jonnala et al., 2002; Garrido et al., 
2003; Hernandez and Terry, 2005; French et al., 2006). Neurexin 1 www.frontiersin.org  March 2011  | Volume 2  | Article 5  |  9
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of various cell types, being stimulatory at low concentration and 
inhibitory at high concentration (Pollman et al., 1999; Ghosh et al., 
2005). The observed mRNA decrease of TGFB2 and its receptor, 
TGFBR2, may indicate an increase in cell proliferation, although this 
remains to be established. Our analysis further showed a moderate 
enhancement of MAPK14 as judged by both mRNA and protein 
expression. MEF2 is one of the many downstream targets regulated 
by MAPK14. In our analysis, the transcription of two members of 
the MEF2 family was induced in the nicotine-treated samples; i.e., 
MEF2D (fold change 1.35; p = 0.008) and MEF2C (fold change 1.27; 
p = 0.177). MEF2 genes are highly expressed in neurons of the CNS 
(Heidenreich and Linseman, 2004; Shalizi and Bonni, 2005) and 
play important roles in neuronal differentiation and maintenance. 
Blocking the function of MEF2 genes may result in the death of 
neurons, whereas their expression can promote neuronal survival 
(Mao et al., 1999; Li et al., 2001; Gaudilliere et al., 2002). Although 
the activity of MEF2 is regulated mainly via its phosphorylation by 
MAPK14 or other kinases, considering the expression induction of 
MAPK14 and MEF2 genes, it may be reasonable to assume the activity 
of MEF2 is enhanced by acute nicotine exposure in SH-SY5Y cells.
In an earlier study, Dunckley and Lukas (2003) analyzed the 
gene expression patterns in SH-SY5Y cells treated with nicotine 
under similar experimental conditions (i.e., 1 mM nicotine for 1 h) 
with different microarray platforms. Among the 17 genes identi-
fied, eight had valid expression measurements in our analysis, and 
their expression patterns were largely consistent in the two stud-
ies. While Dunckley and Lukas (2003) performed a more detailed 
investigation of the relation between the nicotine-regulated genes 
and nAChRs, we here provide a much more broad and comprehen-
sive analysis and description of the biological processes/pathways 
underlying responses to acute nicotine exposure. Results from the 
two studies also indicate that more detailed and comprehensive 
information about the interaction between acute nicotine and 
SH-SY5Y cell line could be obtained.
conclusIon
By profiling the gene expression pattern in SH-SY5Y cell lines 
treated acutely with nicotine, we have identified a set of significantly 
modulated genes. Further, we showed that the majority of these 
differently expressed genes were regulated through the nAChR-
mediated mechanism. From these significantly regulated genes, we 
have detected the enriched biochemical pathways, which included 
those potentially involved in the neuronal response to addictive 
drugs such as nicotine, including glucocorticoid receptor and p38 
MAPK signaling. These findings can help us to understand the 
molecular mechanisms underlying the development of nicotine 
addiction. On the other hand, the identification of these genes and 
pathways further indicates that the physiological consequences of 
acute nicotine exposure are complicated. Thus, further investiga-
tion is necessary in order to obtain a more detailed and compre-
hensive understanding of the interaction between acute nicotine 
treatment and the nervous system.
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neuronal circuitry adaptations induced by heroin self-administration 
were correlated with elevated glucocorticoid production in certain 
brain regions of rats (Weber et al., 2009). Corticosteroid receptor 
modulation of the mesoaccumbens dopamine neurotransmission is 
believed to be a key neurobiological mechanism mediating the effects 
of stress in addiction (Tye et al., 2009). Nicotine can also interact 
with glucocorticoid receptor signaling cascades directly or indirectly. 
Furthermore, the relations between nicotine and glucocorticoids are 
bidirectional; i.e., not only can nicotine affect the hypothalamic–pitui-
tary–adrenal (HPA) axis and circulating glucocorticoids, but adrenal 
steroids can modulate nicotine’s behavioral and physiological actions 
(Caggiula et al., 1998). Nicotine administration elevates plasma cor-
ticosterone in animals (Caggiula et al., 1998). Similarly, both cigaret 
smoking and nicotine infusion rapidly increase circulating cortisol 
concentrations in humans (Caggiula et al., 1998). In human smokers, 
the degree of nicotine addiction is reflected by changes in the sensitiv-
ity of central glucocorticoid receptors (Reuter et al., 2004). Nicotine 
administration to pregnant animals can lead to fetal overexposure to 
maternal glucocorticoid and result in fetal adrenocortical dysfunc-
tion and other diseases after birth (Chen et al., 2007). The significant 
regulation of the corticosteroid receptor signaling pathway by acute 
nicotine exposure provides additional evidence of the importance 
of this pathway in nicotine addiction, and the significantly regulated 
genes in this pathway are excellent candidates for further investiga-
tion. At the same time, the cross-talk between glucocorticoid receptor 
signaling and other pathways, such as MAPK signaling and PI3K/AKT 
signaling (Clark and Lasa, 2003; Gupta et al., 2007), implies that the 
regulation of this pathway indirectly induces modulations in other 
biological processes.
The MAPK signaling pathway is a major modulator of cell growth, 
division, and differentiation (Adams and Sweatt, 2002) and plays a 
key role in mediating neuronal activation induced by dopamine, 
glutamate, and drugs of abuse (Jiao et al., 2007). Nicotine activates 
the MAPK signaling pathway in a variety of tissues and cell types, 
including SH-SY5Y cells (Heusch and Maneckjee, 1998; Tang et al., 
1998; Dajas-Nakayama et al., 2001; Wang et al., 2001; Bailador et al., 
2002). Furthermore, many cellular processes are affected by both 
nicotine and MAPK signaling, such as cell survival and memory 
processing (Levin and Simon, 1998). Despite these known interac-
tions between MAPK signaling and nicotine exposure, our work 
has shown a more detailed pattern of the effect of acute nicotine 
exposure on this pathway. A number of genes were significantly regu-
lated by nicotine exposure (Table 1). There were also genes in this 
pathway that were regulated to a lesser extent (Figure 2). Whereas 
nicotine exposure decreases the amount of mRNA for TGF-beta 2 
(TGFB2), TGFBR2, interleukin 1 receptor (IL1R), and interleukin 1 
receptor-associated kinase 1 (IRAK), as well as a couple downstream 
genes, it also induces the expression of a number of genes, such 
as death-associated protein 6 (DAXX), MAPK14 (p38 MAPK), and 
mads box transcription enhancer factor 2 polypeptide D (MEF2D). 
The regulation pattern of this pathway clearly indicates the cross-talk 
and interaction between different cascades. Earlier studies showed 
that nicotine treatment decreases the amount of TGF-beta mRNA in 
different tissues. For example, nicotine treatment significantly sup-
presses the release of TGF-beta 1 in bovine aortic endothelial cells 
(Cucina et al., 1999) and several other cell lines (Lane et al., 2005). 
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Table A1 | genes significantly expressed in nicotine-treated group.
  Nicotine  Nicotine and 
    mecamylamine
gene symbol gene name p-Value ratio p-Value ratio
ABCD3 ATP-binding cassette, subfamily D (ALD), member 3 0.047 1.17 0.129 1.24
ACAT2 Acetyl-coenzyme A acyltransferase 2 0.046 1.22 7 .03 × 10−3 1.34
ACATE3 Acyl-coenzyme A thioesterase 3 9.09 × 10−3 0.78 0.052 0.86
ADCY8 Adenylyl cyclase 8 0.034 0.80 0.045 0.82
ADRA1B Adrenergic receptor, alpha 1B 4.88 × 10−3 1.31 0.361 1.17
AGT Angiotensinogen 0.039 1.50 0.593 1.10
ALG2 Asparagine-linked glycosylation 2 homolog (yeast, alpha-1,3-mannosyltransferase) 2.75 × 10−3 1.38 0.036 1.37
APC Adenomatosis polyposis coli 0.046 0.83 0.780 0.96
APG4C APG4 (ATG4) autophagy-related homolog C (S. cerevisiae)  0.045 0.83 0.702 1.08
APOA1 Apolipoprotein A-I 0.044 1.68 0.087 1.20
AR Androgen receptor 0.016 0.76 0.939 1.01
ARAF1 V-raf murine sarcoma 3611 viral oncogene homolog 1 0.030 1.24 0.016 1.15
ARPC1A Suppressor of profilin/p41 of actin-related complex 2/3 0.033 1.58 0.051 1.34
ARPC1B Actin-related protein 2/3 complex, subunit 1B 0.042 1.26 0.282 1.11
ASPA Aspartoacylase 0.041 0.75 0.131 1.57
ATF2 Activating transcription factor 2 0.016 0.80 0.026 0.93
ATP5L ATP synthase, H+ transporting, mitochondrial F0 complex, subunit g; F1F0-ATP 0.048 0.74 0.218 1.41
ATP6V1A1 ATPase, H+ transporting, V1 subunit A, isoform 1; ATPase, H+ transporting 0.012 1.28 0.209 1.29
B3GALT3 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 3 0.034 0.70 0.017 0.50
BCL2 B-cell leukemia/lymphoma 2 0.033 1.24 0.473 1.15
BCL2L11 Bcl-12-like 11 (apoptosis facilitator) 0.023 0.65 0.381 0.91
BEGAIN Brain-enriched guanylate kinase-associated protein 1 mRNA, complete cds 0.030 1.26 0.111 1.15
BRCA1 Breast cancer 1 0.033 0.71 0.150 0.79
CACNA1G Calcium channel, voltage-dependent, T type, alpha 1g subunit 0.019 1.38 0.842 1.03
CALCR Calcitonin receptor 0.041 1.25 0.926 1.01
CALCRL Calcitonin receptor-like receptor 0.026 1.63 0.033 1.87
CALD1 Caldesmon 1 0.020 1.27 0.068 1.34
CALM2 Calmodulin 2 0.043 1.39 0.187 1.11
CALR Calreticulin 0.039 1.25 0.769 1.02
CAMK1 CaM-like protein kinase 3.08 × 10−3 0.84 0.235 0.95
CATNA1 Catenin alpha 1 0.043 1.25 0.074 1.19
CATNB Catenin beta 0.011 1.46 0.021 1.20
CCNA2 Cyclin A2 0.022 1.22 0.482 1.05
CCND3 Cyclin D3 8.99 × 10−3 1.32 0.696 0.96
CCNE1 Cyclin E1 0.030 1.64 0.122 1.34
CD3G CD3 antigen, gamma polypeptide 0.029 1.19 0.489 1.13
CDC14B CDC14 cell division cycle 14 homolog B (S. cerevisiae) 0.024 0.56 0.110 0.68
CDC25A Cell division cycle 25 homolog A (S. cerevisiae) 6.02 × 10−3 0.75 7 .82 × 10−4 0.74
CDC2A Cell division cycle 2 homolog A (S. pombe) 0.031 0.79 0.812 0.96
CDC42 Cell division cycle 42 homolog 9.85 × 10−3 0.67 0.798 1.03
CDIPT Phosphatidylinositol synthase 0.030 1.50 0.104 1.31
CDKL2 Cyclin-dependent kinase-like 2 (CDC2-related kinase) 0.046 1.33 0.198 1.44
CDRT1 CMT1A duplicated region transcript 1 0.012 1.40 0.784 0.95
CFLAR CASP8 and FADD-like apoptosis regulator 0.010 1.35 0.313 0.95
CIAO1 WD40 protein Ciao1 0.015 0.64 0.666 0.94
CLCN5 Chloride channel 5 0.011 0.64 9.13 × 10−4 0.80
CLNS1A Chloride channel, nucleotide-sensitive, 1A 0.023 1.31 0.583 1.08
CLSTN3 Calsyntenin 3 0.033 1.33 0.093 1.22
COPS3 COP9 (constitutive photomorphogenic) homolog, subunit 3 (Arabidopsis thaliana) 0.046 1.45 0.734 1.03
COX6B Cytochrome c oxidase, subunit VIb 6.98 × 10−3 1.56 0.344 1.10
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COX7B Cytochrome c oxidase, subunit VIIb 0.032 1.22 0.028 1.21
COX7C Cytochrome c oxidase, subunit VIIc 1.71 × 10−3 1.31 0.150 1.12
COX8B Cytochrome c oxidase, subunit VIIIb 3.37 × 10−3 1.93 0.019 1.84
CREG Cellular repressor of E1A-stimulated genes 1 0.023 1.25 0.621 1.06
CRSP2 Cofactor required for Sp1 transcriptional activation subunit 2 (150 kDa) 4.19 × 10−3 0.67 0.108 0.82
CRYZ Crystallin, zeta 0.035 1.14 0.078 1.17
CSK C-src tyrosine kinase 0.044 1.45 0.110 1.29
CTCF CCCTC-binding factor 0.029 1.18 0.014 1.31
CTNF Ciliary neurotrophic factor receptor 4.85 × 10−3 0.74 0.169 1.34
CYP17A1 Cytochrome P450, family 17 , subfamily a, polypeptide 1 0.043 1.33 0.283 1.23
CYP2F1 Cytochrome P450, subfamily IIF , polypeptide 1 0.022 0.68 0.082 0.77
CYP2R1 Cytochrome P450, family 2, subfamily r, polypeptide 1 0.030 0.84 0.517 1.09
DAB1 Disabled homolog 1 (Drosophila) 0.036 0.55 0.245 0.76
DAXX Death domain-associated protein 6 9.34 × 10−3 1.25 0.501 1.11
DFFA DNA fragmentation factor, 40 kD, beta polypeptide (caspase-activated DNase) 9.62 × 10−3 0.88 0.522 1.03
DIO2 Deiodinase, iodothyronine, type II 0.040 1.27 0.583 1.14
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 4.48 × 10−3 0.66 0.481 1.11
DNCIC2 Dynein, cytoplasmic, intermediate polypeptide 2 0.024 1.38 0.294 0.96
DOCK7 Dedicator of cytokinesis 7 3.57 × 10−3 1.39 0.256 1.26
DRAP1 Dr1 associated protein 1 (negative cofactor 2 alpha) 6.61 × 10−3 0.75 0.025 0.79
DRD4 Dopamine receptor D4 0.013 1.23 0.714 1.02
DRPLA Dentatorubral-pallidoluysian atrophy 5.89 × 10−6 0.70 0.043 1.08
DSTN Destrin 0.012 1.26 0.543 1.04
DUSP1 Dual specificity phosphatase 1 (or protein-tyrosine phosphatase, non-receptor-type, 10) 0.016 1.17 0.138 1.10
EDG4 Similar to endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor 4 2.53 × 10−3 1.34 0.225 0.85
EIF2B Eukaryotic translation initiation factor 2B 8.54 × 10−5 1.31 0.856 0.99
EIF2B5 Eukaryotic translation initiation factor 2B, subunit 5 epsilon 7 .80 × 10−3 1.20 0.029 1.09
EIF4EBP1 Eukaryotic translation initiation factor 4E binding protein 1 0.014 0.65 0.501 0.83
EPHA1 Eph receptor a1 0.033 0.56 0.046 0.61
FASN Fatty acid synthase 0.017 1.21 0.695 0.97
FGF13 Fibroblast growth factor 13 0.034 1.37 0.028 1.26
FGG Fibrinogen, gamma polypeptide 0.014 1.22 0.583 1.04
FKRP Fukutin related protein 0.040 0.70 0.737 0.95
FOS Fos oncogene 0.031 1.28 0.414 1.14
FOXO1 Forkhead box 1 8.70 × 10−4 0.52 0.627 1.12
FXC1 Similar to Mitochondrial import inner membrane translocase subunit TIM9 B (fracture 
callus protein 1) 
0.043 1.23 0.852 0.97
GABARAP Gamma-aminobutyric acid receptor-associated protein 0.012 0.79 0.906 1.01
GABRA3 Gamma-aminobutyric acid (GABA_A) receptor, subunit alpha 3 6.52 × 10−4 0.77 0.113 0.83
GABRD GABA(A) receptor delta subunit 0.026 0.63 0.861 1.03
GAL Galanin 0.021 1.39 0.329 1.07
GALNT10 UDP-N-acetyl-alpha-d-galactosamine:polypeptide N-acetylgalactosaminyltransferase 10 1.37 × 10−3 1.33 0.662 1.05
GEMIN5 Gem (nuclear organelle) associated protein 5 0.015 0.66 0.511 0.95
GLCCI1 Glucocorticoid induced transcript 1 0.014 0.71 0.039 0.55
GLI1 GLI-Kruppel family member GLI1 0.010 1.33 0.869 0.99
GLI3 GLI-Kruppel family member Gli 3 0.037 0.87 0.012 0.67
GLUD1 Glutamate dehydrogenase 0.047 1.28 1.73 × 10−3 1.36
GNA15 Guanine nucleotide binding protein, alpha 15 0.012 1.41 0.276 1.29
GPAA1 GPI anchor attachment protein 1 0.018 0.83 0.602 0.89
GRIK1 Glutamate receptor, ionotropic, kainate 1 0.034 0.67 0.074 0.79
GRM2 Glutamate receptor, metabotropic 2 5.59 × 10−3 0.68 0.152 0.76
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GSPT1 G1 to phase transition 1 0.035 0.89 0.754 1.02
GSTM6 Glutathione S-transferase, mu6 7 .76 × 10−3 1.41 1.17 × 10−3 1.42
GTF2H2 General transcription factor IIH, polypeptide 2 (44 kDa subunit) 0.011 0.54 0.023 0.64
GTF3C5 General transcription factor IIIC, polypeptide 5 0.036 1.36 0.018 1.36
GUK1 Guanylate kinase 1 0.019 0.57 0.821 1.06
H1F0 H1 histone family, member 0 0.016 1.22 0.561 1.07
HBA Hemoglobin X, alpha-like embryonic chain in Hba complex 0.029 0.72 0.030 1.15
HBB Hemoglobin beta chain complex 7 .12 × 10−4 0.73 0.153 0.61
HBG1 Hemoglobin, gamma A 4.84 × 10−3 1.45 3.32 × 10−4 1.71
HHL RAB GTPase activating protein 1-like 0.042 1.27 0.034 1.27
HIATL2 Hippocampus abundant gene transcript-like 2 0.033 0.69 0.507 0.88
HIS4 Histone 4 protein 0.045 1.19 0.084 1.25
HMGN1 High mobility group nucleosomal binding domain 1 0.014 1.42 0.851 1.01
HRMT1L2 Heterogeneous nuclear ribonucleoproteins methyltransferase-like 2 (S. cerevisiae) 0.019 0.79 0.457 0.91
HTR3A 5-Hydroxytryptamine receptor 3a (Htr3a) 1.77 × 10−3 1.65 0.783 1.07
IDG3G Isocitrate dehydrogenase 3 (NAD + ), gamma 0.038 1.41 0.020 1.31
IGF1R Insulin like growth factor receptor 1 0.035 0.70 0.340 1.26
IGSF4A Cell adhesion molecule 1 6.48 × 10−4 1.21 0.957 1.00
IKBKG Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma 0.031 1.27 0.255 1.15
IL6R Interleukin 6 receptor 5.48 × 10−3 1.17 0.265 0.94
IL6RA Interleukin 6 receptor, alpha 0.044 0.62 0.721 1.05
IL6ST Interleukin 6 signal transducer 9.39 × 10−3 0.74 0.182 0.89
IL7R Interleukin 7 receptor 0.047 1.37 0.026 1.36
IMPA1 Lithium-sensitive myo-inositol monophosphatase A1 0.015 1.25 0.388 1.22
ING4 Inhibitor of growth family, member 4 0.024 1.25 0.602 0.96
IRAK3 Interleukin-1 receptor-associated kinase 3 0.041 0.67 0.490 1.10
ITGB1 Integrin beta 1 0.043 0.86 0.776 0.97
ITPKA Inositol 1,4,5-trisphosphate 3-kinase A 7 .66 × 10−3 1.14 1.91 × 10−4 1.50
ITPR5 Inositol 1,4,5-triphosphate receptor 5 2.67 × 10−3 0.81 0.015 0.83
JAK3 Janus kinase 3 0.024 0.80 0.206 0.84
KCMF1 Potassium channel modulatory factor 1 0.034 0.76 0.347 0.86
KCNB2 Potassium voltage-gated channel, Shab-related subfamily, member 2 0.039 0.80 3.60 × 10−3 0.62
KCNC2 Potassium voltage-gated channel, Shaw-related subfamily, member 3 0.017 0.86 0.164 0.91
KCNK1 Putative potassium channel TWIK 0.012 1.20 0.095 1.15
KCNMA1 Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 1.93 × 10−3 1.45 0.443 1.28
KITL Kit ligand 1.05 × 10−3 0.77 0.108 0.83
KPNB1 Karyopherin (importin) beta 1 5.08 × 10−3 1.20 0.086 1.19
LAG3 Lymphocyte-activation gene 3 0.012 0.78 0.038 0.81
LAMB2 Laminin beta 0.043 1.54 0.539 1.06
LAMC1 Lamnin gamma 5.02 × 10−3 0.76 0.205 0.87
LAMR1 Laminin receptor 1 0.044 1.21 0.045 1.20
LIMK1 Lim kinase LIM motif-containing protein kinase 1 0.040 0.71 0.147 0.69
LMO1 LIM domain only 3 0.023 0.82 0.451 0.86
LPL Lipoprotein lipase 0.020 0.74 0.990 1.00
LRP1 Low density lipoprotein receptor-related protein 1 8.86 × 10−3 0.74 0.800 0.98
LRP4 Low density lipoprotein receptor-related protein 4 2.93 × 10−3 1.41 0.748 1.03
LTBP3 Latent transforming growth factor beta binding protein 3 0.030 1.27 0.428 1.06
MAF Avian musculoaponeurotic fibrosarcoma (v-maf) AS42 oncogene homolog 0.012 1.34 0.041 0.90
MAP2K5 Mitogen-activated protein kinase kinase 5 2.96 × 10−3 0.86 0.660 0.96
MAP3K7IP1 Mitogen-activated protein kinase kinase kinase 7 interacting protein 1 7 .63 × 10−3 1.45 0.950 0.99
MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 3.33 × 10−4 0.69 1.48 × 10−3 0.64
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MAPK14 Mitogen-activated protein kinase 14 8.65 × 10−3 1.35 0.445 1.12
MAS1 MAS1 oncogene 0.014 0.79 0.944 0.99
MATR3 Matrin 3 0.011 0.73 0.512 0.90
MCM5 Minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae) 0.041 1.10 0.181 1.12
MEF2D Myocyte enhancer factor 2d 7 .73 × 10−3 1.35 0.152 1.31
MKLN1 Muskelin 1, intracellular mediator containing kelch motifs 4.12 × 10−5 0.68 0.056 0.85
MLYCD Malonyl-CoA decarboxylase 8.54 × 10−3 1.66 0.023 1.46
MME Membrane metallo endopeptidase 0.024 1.21 0.473 1.02
MRE11A Meiotic recombination 11 homolog A (S. cerevisiae) 0.036 0.70 0.300 0.85
MRPL39 Mitochondrial ribosomal protein L39 1.22 × 10−3 0.78 1.20 × 10−3 0.69
MRPS14 Mitochondrial ribosomal protein S14 5.45 × 10−3 0.71 0.945 1.01
MRPS17 Mitochondrial ribosomal protein S17 0.019 0.82 0.695 0.91
MRPS7 Mitochondrial ribosomal protein S7 7 .10 × 10−3 1.62 0.852 0.98
MTC MT-protocadherin (KIAA 1775) 3.55 × 10−4 1.29 0.984 1.00
MTEFR Transcription termination factor, mitochondrial-like 0.025 0.66 0.542 0.87
MYO7A Myosin VIIA 7 .50 × 10−3 0.64 0.361 0.88
NCBP1 Nuclear cap binding protein subunit 1, 80 kDa 2.15 × 10−3 1.36 0.750 1.06
NDUFA4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4 3.41 × 10−3 1.40 0.909 1.01
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1 0.022 1.65 0.043 1.37
NEU3 Neurotrophic tyrosine kinase, receptor, type 1 0.034 1.25 0.040 1.36
NEUD4 Neuronal d4 domain family member 0.018 1.70 0.029 1.36
NFATC3 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 0.010 0.74 0.084 0.77
NFE2L2 Nuclear factor, erythroid derived 2, like 2 1.38 × 10−4 1.12 0.315 0.85
NGFA Nerve growth factor, alpha 0.029 1.20 0.036 1.15
NGFR Nerve growth factor receptor 4.51 × 10−3 1.46 0.018 1.30
NINJ1 Ninjurin 1 0.031 0.72 0.111 0.73
NLK1 Nemo like kinase 3.33 × 10−3 0.55 0.022 0.70
NOL5 Nucleolar protein 5 3.10 × 10−3 0.80 0.071 0.82
NR2F1 Nuclear receptor subfamily 2, group F , member 1 1.74 × 10−3 1.33 0.211 1.10
NRF1 Nuclear respiratory factor 1 0.040 0.83 0.166 0.66
NRXN1 Neurexin1 7 .69 × 10−3 0.78 1.73 × 10−4 0.74
NSG1 Neuron-specific gene family member 1 0.039 0.84 0.309 0.95
NUCB Calcium-binding protein 0.023 1.35 0.126 1.12
NXPH4 Neurexophilin4 3.87 × 10−3 1.37 0.048 1.46
OGDH Oxoglutarate dehydrogenase 0.031 1.27 0.947 0.99
OGN Osteoglycin  1.48 × 10−3 0.57 0.261 0.84
PBX4 Pre-B-cell leukemia transcription factor 4 7 .99 × 10−4 1.59 8.04 × 10−3 1.38
PCP4 Purkinje cell protein 4 0.011 0.75 0.030 0.67
PDLIM2 PDZ and LIM domain 2 4.91 × 10−3 1.99 0.014 1.55
PHYHIP Phytanoyl-CoA hydroxylase interacting protein 5.61 × 10−3 0.88 0.023 1.04
PIGQ Glycosylphosphatidylinositol 1 homolog 0.013 1.36 0.035 1.18
PIK3CG Phosphoinositide-3-kinase, catalytic, gamma polypeptide 0.049 1.30 0.657 1.08
PIR51 RAD51 associated protein 1 0.050 1.28 0.631 0.96
PLA2G4A Phospholipase A2, group IVA (cytosolic, calcium-dependent) 3.26 × 10−3 1.42 0.221 1.25
PMP22 Peripheral myelin protein 22 5.96 × 10−3 1.17 0.118 1.07
POLE3 Polymerase (DNA directed), epsilon 3 (p17 subunit) 9.98 × 10−3 1.39 0.124 1.18
PPIA Peptidylprolyl isomerase A 0.040 1.38 0.130 1.17
PPM1L Protein phosphatase 1 (formerly 2C)-like 0.032 1.35 0.212 1.31
PPP1CA Protein phosphatase 1, catalytic subunit, alpha isoform 0.020 1.21 9.25 × 10−3 1.21
PPT Palmitoyl-protein thioesterase 0.050 1.56 0.166 1.10
PRDX6 Peroxiredoxin 6 0.023 1.22 0.341 1.13
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PRRX1 Paired related homeobox 1 0.050 1.16 0.805 1.03
PSCDBP Pleckstrin homology, Sec7 , and coiled-coil domains, binding protein 9.26 × 10−3 0.89 0.052 0.81
PSMB4 Proteasome (prosome, macropain) subunit, beta type, 4 2.14 × 10−3 1.23 0.235 1.09
PSMD10 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 10 0.025 1.17 0.875 1.01
PSMD14 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 0.029 0.70 0.154 0.79
PSMD2 26S proteasome, non-ATPase, 2 2.37 × 10−3 1.54 0.033 1.25
PTH Parathyroid hormone 0.040 1.19 0.608 0.96
PTP4A2 Protein–tyrosine phosphatase type 4a, member 2 0.027 1.24 0.011 1.24
PTPRZ1 Protein–tyrosine phosphatase, receptor type, Z1 0.041 0.90 0.597 1.05
RAB1 Ras-related protein 0.036 1.23 0.029 1.36
RAB7 Ras 7member of RAS oncogene family 0.042 0.80 0.048 0.85
RAB9 Ras 9 member of RAS oncogene family 0.036 1.32 0.377 1.15
RAD1 RAD1 homolog (S. pombe) 6.01 × 10−4 0.69 0.046 0.78
RAD51 RAD51 homolog (S. cerevisiae) 0.013 1.45 0.131 1.48
RALA V-ral simian leukemia viral oncogene homolog A (Ras-related) 8.17 × 10−3 1.74 0.096 1.27
RAPGEF3 Rap guanine nucleotide exchange factor (GEF) 3 0.032 0.84 0.158 0.89
RASA2 RAS p21 protein activator 2 0.034 0.73 0.537 1.18
RBL1 Retinoblastoma-like 1 (p107) 0.046 0.73 0.111 0.73
RIS2 Retroviral integration site 2 0.024 0.74 0.244 0.88
RISP Ubiquinol–cytochrome c reductase, Rieske iron–sulfur polypeptide 1 0.048 0.76 0.159 0.84
RNF20 Ring finger protein 20 0.017 0.69 0.058 0.76
RPL18 Ribosomal protein L18 0.031 0.75 0.033 0.80
RPL29 Ribosomal protein L29 1.43 × 10−3 1.50 0.110 1.19
RPL36 Ribosomal protein L36 0.031 0.85 0.979 1.00
RPS26 Ribosomal protein S26 0.032 1.57 0.192 1.14
RPS27L Ribosomal protein S27 0.032 1.44 0.201 1.13
RPS6KA2 Ribosomal protein S6 kinase, 90kD, polypeptide 2 5.70 × 10−4 0.82 0.708 0.95
RPS6KB1 Ribosomal protein S6 kinase, 70kD, polypeptide 1 0.037 1.28 0.017 1.25
SCN11A Sodium channel, voltage-gated, type11, alpha polypeptide 0.024 1.45 0.346 0.86
SCO1 Similar to SCO cytochrome oxidase deficient homolog 1 (yeast) 0.033 0.84 0.641 1.05
SCUBE2 Signal peptide, CUB domain, EGF-like 2 2.96 × 10−3 0.67 0.010 0.70
SCYA20 Small inducible cytokine subfamily A20 4.02 × 10−3 0.75 0.288 0.91
SDHB Succinate dehydrogenase complex, subunit A, flavoprotein 6.23 × 10−3 1.32 0.181 0.87
SDHC Succinate dehydrogenase complex, subunit C 0.017 1.18 0.035 1.13
SECISBP2 Selenocysteine insertion sequence-binding protein 2 8.27 × 10−3 0.76 0.367 1.03
SERPINC1 Serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1 0.040 1.35 0.152 1.37
SFN Stratifin 0.022 1.14 0.635 1.04
SKIL Ski like 8.52 × 10−3 1.31 2.44 × 10−4 1.17
SLC18A2 Solute carrier family 18 member 2 0.023 1.46 0.144 0.91
SLC29A1 Solute carrier family 29 (nucleoside transporters), member 1 0.021 0.73 0.164 1.41
SLC2A14 Solute carrier family 2 (facilitated glucose transporter), member 14 4.37 × 10−3 0.68 0.032 0.73
SLC2A4 Solute carrier family 2 (facilitated glucose transporter), member 4 0.030 1.58 0.221 1.32
SLC35D2 Solute carrier family 35, member D2 0.024 1.39 0.016 1.61
SLC35F5 Solute carrier family 35, member F5 0.018 0.73 0.890 0.98
SLC5A3 Solute carrier family 5 (inositol transporters), member 3 4.51 × 10−4 0.63 4.60 × 10−3 0.76
SLC6A4 Solute carrier family 6, member 4 (serotonin transporter) 3.78 × 10−6 0.62 0.134 1.08
SLC8A2 Solute carrier family 8 (sodium/calcium exchanger), member 2 0.032 1.30 0.194 0.93
SMAD2 MAD homolog 2 (Drosophila) 0.035 0.83 0.323 1.09
SNCA Synuclein, alpha 5.13 × 10−3 0.71 0.523 0.87
SOX6 SoxLZ/Sox6 leucine zipper binding protein in testis 0.027 1.17 0.937 0.99
SPEN SMART/HDAC1 associated repressor protein 0.024 0.79 0.013 0.68
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STAT5A Signal transducer and activator of transcription 5a 0.021 1.25 0.044 1.24
SWAP70 Switch-associated protein 70 0.032 0.61 0.646 0.87
SYN2 Synapsin 2 0.014 1.25 0.988 1.00
SYT2 Synaptotagmin 2 1.36 × 10−3 1.24 0.192 1.17
SYT7 Synaptotagmin 7 5.30 × 10−3 1.69 0.492 1.08
TAC2 Tachykinin 2 3.45 × 10−3 0.72 0.988 1.00
TBC1D17 TBC1 domain family, member 17 0.046 1.43 0.051 1.21
TBP1 Tat-binding protein-1 0.041 0.77 0.108 0.80
TCFEB Transcription factor EB 6.61 × 10−5 0.76 0.518 0.97
TDG Thymine DNA glycosylase 0.032 0.57 0.108 0.70
TF Transferrin 0.028 0.73 0.045 0.70
TFR Transferrin receptor 5.66 × 10−3 1.32 0.893 1.02
TGFB2 Transforming growth factor, beta 2 5.58 × 10−5 0.74 0.019 0.71
TGFBR2 Transforming growth factor, beta receptor 2 6.22 × 10−3 0.57 0.913 0.98
TNFRSF10B Tumor necrosis factor receptor superfamily, member 10b 0.042 1.43 0.134 1.22
TRAF6 Tnf receptor-associated factor 6 0.035 0.75 0.654 0.94
TRG Thyroid regulating gene 0.019 0.69 0.090 0.71
TRNT1 TRNA nucleotidyl transferase, CCA-adding1 0.022 0.76 0.538 0.97
TRP53 Transformation-related protein 53 6.94 × 10−3 1.32 0.252 1.08
TSGA13 Testis specific gene A13 2.29 × 10−3 1.07 5.98 × 10−3 1.41
TUBB5 Beta-tubulin, 5 0.017 1.19 0.079 1.08
UAP1 Similar to UDP-N-acteylglucosamine pyrophosphorylase 1 homolog 0.021 1.24 0.526 0.93
UBE1X Ubiquitin-activating enzyme e1, Chr X 0.019 1.14 0.761 0.99
UBE2A Ubiquitin-conjugating enzyme E2A 0.018 1.54 0.250 1.10
UBE2G1 Ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, C. elegans) 0.023 0.88 0.425 1.22
UBQLN1 Ubiquilin 1 0.030 1.18 0.763 0.96
UBQLN3 Ubiquilin 3 0.016 0.58 0.036 0.60
UQCRFS1 Ubiquinol–cytochrome c reductase, Rieske iron–sulfur polypeptide 1 3.11 × 10−3 1.53 0.832 0.98
USP28 Ubiquitin-specific protease 28 8.60 × 10−3 1.29 0.062 1.29
VAMP3 Vesicle-associated membrane protein 3 0.036 1.21 9.68 × 10−3 1.12
VCL Vinculin 2.10 × 10−3 1.39 3.10 × 10−3 1.30
VEGFA Vascular endothelial growth factor A 0.038 0.84 0.513 0.92
VGLL2 Vestigial like 2 homolog (Drosophila)  0.014 1.21 0.501 1.02
VIL1 Villin1 0.016 0.65 9.82 × 10−3 0.79
WNT1 Wingless-related MMTV integration site 1 0.042 1.17 0.493 1.07
XCL2 Chemokine (C motif) ligand 2 0.023 1.38 0.073 1.33
XTP2 HBxAg transactivated protein 2 0.031 0.88 0.308 0.90
YWHAH Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta 
polypeptide
0.037 1.21 0.069 0.87
ZAP70 Zeta-chain (TCR) associated protein kinase 2.07 × 10−4 1.36 0.139 1.09
ZFP98 Zinc finger protein 98 8.22 × 10−4 1.21 0.616 0.97
ZNF189 Zinc finger protein 189 0.035 0.79 0.264 0.80
ZNF286 Zinc finger protein 286 0.012 1.18 0.381 1.09
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